Biocon share price today: HSBC revises target price to Rs 480 from Rs 455 for Biocon
HSBC remains positive on Biocon’s long term prospects for biosimilars and believes that improved execution of launches in the US and a renewed focus for MoW markets should help it to better pick-up biosimilars sales. Market opportunities remain abundant in DM (28 products in the pipeline with cumulative brand sales of USD 80 bn).
HSBC makes 1%-7.5% changes in FY21-23 earnings estimates per current outlook and roll forward valuations to March 2023e from December 2022e: Reuters